M.D., Ph.D.
Hematologist-Oncologist
2012, American Board of Internal Medicine, Hematology
2010, American Board of Internal Medicine, Medical Oncology
2007, American Board of Internal Medicine, Internal Medicine
2000, Ph.D., Yaroslavl Medical Academy, Russia
1997, M.D., summa cum laude, Yaroslavl Medical Academy, Russia
2007-2010, Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts
2004-2007, Medicine, Brown University School of Medicine, Providence, Rhode Island
2004-2005, Medicine, Brown University School of Medicine, Providence, RI
2020-Present, Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Associate Director, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
2020-Present, Translational Medicine Chair, SWOG Lymphoma
2014-2020, Assistant & Associate Professor of Medicine, Hematology - Oncology, OHSU, Portland, OR
2010-2014, Assistant Professor of Medicine, Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2001-2004, Research Scholar, Tufts University School of Medicine, Boston, MA
2000-2001, Instructor, Department of Medicine, Yaroslavl Medical Academy, Russia
1998-1999, Instructor, Department of Pathophysiology, Yaroslavl Medical Academy, Russia
Alexey Danilov, M.D., Ph.D., is an accomplished researcher and globally recognized expert in chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. At City of Hope® Cancer Center Duarte, he is a professor of hematology and hematopoietic stem cell transplantation and serves in a variety of leadership roles in both the Toni Stephenson Lymphoma Center and City of Hope’s early clinical therapeutics program.
Dr. Danilov—who is both a Leukemia & Lymphoma Society Scholar and the principal investigator on numerous research projects with funding from organizations such as the National Cancer Institute (NCI), the American Society of Hematology, the Lymphoma Research Foundation and the Leukemia & Lymphoma Society—has developed and led dozens of clinical trials exploring innovative targeted therapies and immunotherapies for blood cancers. Through collaborations with the NCI, pharmaceutical companies and the Southwest Oncology Group’s Lymphoma Committee, Dr. Danilov has played an influential role in advancing global drug development efforts for hematologic malignancies.
At City of Hope, Dr. Danilov oversees early-phase clinical research initiatives as part of the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network. In his role with the Toni Stephenson Lymphoma Center, he steers both clinical and translational research focused on leukemia and lymphoma. A strong advocate of translational medicine, Dr. Danilov’s laboratory is dedicated to bridging scientific discoveries with patient care—bringing innovations from the bench to the bedside to benefit patients at Citi of Hope and beyond.